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ABSTRACT 
Among adults with CF, medication adherence is low and reasons for low adherence are poorly 
understood. Our previous H[SORUDWRU\ VWXG\ VKRZHG WKDW VWURQJHU µKDELW¶ LH DXWRPDWLFDOO\
experiencing an urge to use a nebuliser) was associated with higher nebuliser adherence. We 
performed a secondary analysis of  pilot trial data (n=61) to replicate the earlier study and 
determine whether habit-adherence association exists in other cohorts of adults with CF. In this 
study, high adherers also reported stronger habit compared to low adherers. Habit may be a 
promising target for self-management interventions. 
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INTRODUCTION 
 
Adherence to preventative inhaled treatments is associated with better health outcomes in cystic 
fibrosis (CF) but adherence levels are generally low.[1] Effective adherence interventions are 
lacking,[2] and reasons for low adherence are poorly understood. Studies of adherence 
determinants in CF have tended to focus on treatment burden and conscious motivational factors 
such as treatment beliefs.[2] However, behavioural theories such as the COM-B model (Capability, 
Opportunity, Motivation and Behaviour) propose a wider range of adherence predictors, including 
automatic processes such as habit.[3] Indeed, habit may better predict treatment adherence 
compared to conscious motivational factors.[4] Although commonly used to refer to frequent 
repetitive actions, within psychology WKHWHUPµKabit¶ describes a non-conscious process by which 
situational cues (e.g. time of day) automatically prompt an impulse to perform an action (i.e. using 
nebuliser).[5] 
 
Because they are automatically cued, habitual behaviours require little conscious cognitive effort to 
enact.[5] Habits form through consistent repetition of a specific action in a specific context, which 
gradually shifts the cognitive control over initiation of action from reflective to automatic processes, 
such that encountering the context becomes sufficient to elicit the associated action.[5] This 
reduces dependence on conscious attention or deliberative processes to initiate action. Habitual 
behaviours are thus thought to persist even if attention and conscious motivation wane.[5] 
 
Our earlier exploratory mixed-methods study in Sheffield showed that high adherers had stronger 
habit than did low adherers.[6] High adherers also described DXWRPDWLFDOO\ µUHPHPEHULQJ¶ WRXVH
their nebulisers; for example, one participant experienced the urge to use his nebuliser after 
walking his dog every morning.[6] To determine whether the habit-adherence association exists in 
other cohorts of adults with CF, we performed a secondary analysis using data prospectively 
collected during a pilot randomised controlled trial (ACtiF pilot, ISRCTN13076797). This two-centre 
pilot was primarily designed to explore the use of CFHealthHub, a software platform which delivers 
a complex intervention to support habit formation and self-management with inhaled therapies 
among adults with CF. 
 
 
METHODS 
 
Participants were recruited from the Wolfson CF Centre (n=29) and the Wessex Adult CF Centre 
(n=32) from June-September 2016. Nebuliser habit strength was measured at the point of 
recruitment using the Self-Report Behavioural Automaticity Index (SRBAI).[7] The SRBAI consists 
of four statements HJµdeciding to use my nebuliser is something I do DXWRPDWLFDOO\¶with which 
participants rate agreement on a 1-5 scale, where 5 represents strongest habit. Item scores were 
then summed to create a scale ranging from 4 (weakest habit) to 20 (strongest habit). Adherence 
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data was downloaded from chipped nebulisers (eTrack®) in the 3-month period following the point 
of recruitment DQGFDOFXODWHGDV µQRUPDWLYHDGKHUHQFH¶,[8] a measure that takes into account a 
SHUVRQ¶V FKDUDFWHULVWLFV ZKHQ GHILQLQJ WKH PLQLPXP UHTXLUHG WUHDWPHQW UHJLPHQ (see online 
appendix). Participants were divided into three adherence categories (<50% for low adherence, 
50-79.9% for moderate adherencefor high adherence) to mirror the analysis of our earlier 
Sheffield study.[6] These adherence categories were used in various other CF-related studies and 
were chosen based on the relationship with health outcomes.[1, 9]  
 
Outcomes data (e.g. FEV1) and other psychological measures were also collected as part of the 
pilot trial (e.g. beliefs about medicine necessity and concerns, which were combined in the Beliefs 
about Medicines Questionnaire ± specific nebuliser adherence, BMQ,[10] a validated self-report 
tool that was customised for the pilot trial to identify perceived necessities and concerns for 
nebuliser treatment). Further details of the study variables are provided in the online appendix. 
Non-parametric statistical analysis methods were used, as well as multiple ordinal regression with 
adherence category as the dependent variable.  
 
 
RESULTS 
 
High adherers (n=7) had lower prior-year IV use and tended to have higher %FEV1 at baseline. 
High adherers reported stronger habit (median 18.0, IQR 14.0-20.0) than did low adherers (n=46; 
median 9.0, IQR 4.8-12.0), see Table 1. Conversely, high adherers reported lower concerns 
(median 1.6, IQR 1.3-1.7) than did low adherers (median 2.3, IQR 1.9-2.6). In a multiple ordinal 
regression model with both habit and concerns scores, only habit was associated with adherence. 
The adjusted odds ratio indicated that 1 unit increase in habit score was associated with a 31% 
increase in the odds of being in the next-higher adherence category (95% CI 12-54%), see 
footnote of Table 1.  
 
This two-centre pilot was not powered to determine the association between adherence and health 
outcomes. The absence of association between adherence and outcomes should not, therefore, be 
interpreted as evidence of absence.[11] 
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Table 1: Clinical characteristics and psychological factors among three groups of adults with CF 
 
Low 
adherence,  
i.e. <50% 
 
n = 46 
Moderate 
adherence,  
i.e. 50-79.9% 
 
n = 8 
High 
adherence,  
LH 
 
n = 7 
 
 
P-value µ 
 
% Normative adherence, median (IQR) 
 
 
Clinical characteristics: 
 
Age in years, median (IQR) 
 
Female, n (%) 
 
Baseline %FEV1, median (IQR) 
 
Prior-year IV days, median (IQR) 
 
IV days during trial, median (IQR) 
 
Quality of life (CFQ-R), median (IQR) 
 
 
Psychological factors: 
 
Anxiety (GAD) score, median (IQR) 
 
Depression (PHQ-8) score, median (IQR) 
 
Intention (COM-B) score, median (IQR) 
 
Necessity (BMQ) score, median (IQR) 
 
Concerns (BMQ) score,* median (IQR) 
 
Habit (SRBAI) scores,* median (IQR) 
 
 
15.8 (4.5 ± 35.4) 
 
 
 
27.4 (21.7 ± 37.1) 
 
22 (47.8) 
 
49.5 (43.1 ± 66.4) 
 
28 (13 ± 47) 
 
14 (0 ± 23) 
 
50 (28 ± 78) 
 
 
 
4 (1 ± 7) 
 
6 (3 ± 11) 
 
7 (5 ± 7) 
 
3.1 (2.7 ± 3.8) 
 
2.3 (1.9 ± 2.6) 
 
9.0 (4.8 ± 12.0) 
 
65.5 (56.0 ± 75.8) 
 
 
 
23.7 (18.4 ± 32.0) 
 
5 (62.5) 
 
83.5 (43.1 ± 66.4) 
 
15 (4 ± 53) 
 
15 (0 ± 30) 
 
64 (34 ± 88) 
 
 
 
1 (1 ± 4) 
 
6 (3 ± 13) 
 
7 (7 ± 7) 
 
3.3 (2.8 ± 3.9) 
 
1.9 (1.5 ± 2.3) 
 
14.5 (11.3 ± 18.3) 
 
91.5 (80.2 ± 96.7) 
 
 
 
26.1 (21.2 ± 37.5) 
 
1 (14.3) 
 
79.7 (52.7 ± 89.1) 
 
0 (0 ± 10) 
 
0 (0 ± 0) 
 
67 (44 ± 78) 
 
 
 
0 (0 ± 5) 
 
4 (2 ± 4) 
 
7 (5 ± 7) 
 
3.4 (2.7 ± 4.6) 
 
1.6 (1.3 ± 1.7) 
 
18.0 (14.0 ± 20.0) 
 
 
 
 
 
 
0.616  
 
0.164 
 
0.068 
 
0.012 
 
0.160 
 
0.306 
 
 
 
0.186 
 
0.389 
 
0.256 
 
0.496 
 
0.030 
 
< 0.001 
 
µ
 All p-values were calculated using Kruskal-Wallis H test, except the p-value for gender ZDVFDOFXODWHGXVLQJ)LVKHU¶VH[DFWWHVW 
 
* Since concerns and habit scores were associated with adherence, both scores were included as covariates in a multiple ordinal 
regression model with adherence category as the dependent variable. In this model, only habit strength was independently associated 
with adherence: 
Pseudo-R2 of model = 0.408 (Nagelkerke); model Ȥ2 (2) = 22.9, p <0.001. 
Adjusted odds ratio for Concerns score = 0.344 (95% CI 0.103 to 1.152, p-value 0.083) 
Adjusted odds ratio for Habit score = 1.313 (95% CI 1.123 to 1.536, p-value 0.001) 
 
 
 
DISCUSSION 
 
We had previously found the association between stronger habit and higher nebuliser adherence in 
Sheffield (for our earlier study, adherence was assessed retrospectively in the 1-year pre-
recruitment period). In this study, our earlier finding has been replicated in a larger sample of 
adults with CF from two other centres (note that adherence was measured prospectively over a 3-
month post-recruitment period in this study). This suggests that habit ± that is, automatically 
experiencing an urge to use the nebuliser in certain settings, due to learned associations between 
nebuliser use and cues within those settings ± may be consistently associated with treatment 
adherence among adults with CF. 
 
Whilst habit is not the only factor associated with nebuliser adherence, appreciating the importance 
of both non-conscious motivation (e.g. habit) and conscious motivation (e.g. treatment beliefs) 
could lead to more effective adherence interventions.[3, 5] The relationship between habit and 
adherence over time is complex and dynamic; initial repetitions of a behaviour (e.g. using a 
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nebuliser) will strengthen habit, which subsequently acquires the potential to direct subsequent 
performance.[5] While studies of the formation of adherence habits are needed to reveal the causal 
direction or directions of the habit-adherence relationship we observed, our results are nonetheless 
consistent with the suggestion that, once formed, habit may determine subsequent adherence.[5, 
6] Habit-formation advice, i.e. encouraging the use of treatments in specific and unchanging 
contexts, so that associations may develop between those contexts and treatment adherence, is 
simple to deliver [5] and could be part of a comprehensive package of interventions to support 
adherence. Habit strength might also be usefully assessed as an intervention outcome. 
 
It is difficult to establish the causal direction of observed relationships in this study and the small 
sample size is a limitation (see online appendix for more detailed discussion regarding the 
limitation of the study). Nonetheless, we have replicated the Sheffield findings in an independent 
cohort, which suggests that the habit-adherence association is not just a peculiarity specific to a 
single adult CF centre. Two further studies are now underway to explore habit formation in more 
detail using CFHealthHub in a 19-centre RCT (ISRCTN55504164) and a three-centre improvement 
collaborative (ISRCTN14464661). We anticipate these studies will extend our understanding of the 
role of habit in sustained behaviour change among adults with CF. 
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Appendix A: Further explanation and details regarding the study variables 
 
Demographic and health outcomes data e.g. age, gender, %FEV1, IV antibiotics use and quality of life 
were collected as part of the pilot trial procedure. Baseline %FEV1 collected at the time of recruitment 
was measured during a period of clinical stability and calculated using the Global Lung Function Initiative 
(GLI) equation.[1] IV antibiotic days were recorded for the 1-year period prior to recruitment, and for 6 
months during the pilot trial. Quality of life at baseline was self-reported using all six relevant statements 
from the Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain,[2] HJ µ+DYH \RX EHHQ
FRXJKLQJ GXULQJ WKH GD\"¶ Į    7KH &)4-R scale ranged from 0 (lowest quality of life) to 100 
(highest quality of life). 
 
Adherence data were downloaded from chipped nebulisers (eTrack®) in the 3-month period following the 
point of recruitment; and calculated as ZDVFDOFXODWHGDV µQRUPDWLYHDGKHUHQFH¶ µ1RUPDWLYH adherence 
WDNHV LQWRDFFRXQWDSHUVRQ¶VFKDUDFWHULVWLFVZKHQGHILQLQJWKHPLQLPXPUHTXLUHGWUHDWPHQWUHJLPHQ [3] 
&DOFXODWLRQ RI µQRUPDWLYH DGKHUHQFH¶ LQYROYHV DGMXVWLQJ WKH GHQRPLQDWRU EDVHG RQ WKH FOLQLFDO
characteristics of a person with CF, adjusting the numerator by capping daily maximum nebuliser use at 
100% (also accounting for doses taken after midnight) and adjusting the numerator by accounting for 
dose spacing of inhaled antibiotics. For example, a person with chronic Pseudomonas aeruginosa 
infection should take at least a nebulised mucolytic and an antibiotic. Thus the denominator for a person 
with chronic Pseudomonas aeruginosa infection will be at least 3 (1x dornase alfa, 2x antibiotic). If a 
person with chronic Pseudomonas aeruginosa infection only agreed to use nebulised dornase alfa once 
daily (which is 1 nebuliser/day), even if they take every does of their dornase alfa, the µnormative 
adherence¶ is only 33%. This is because in the calculation of µnormative adherence¶, the denominator is 
at least 3 nebulisers/day for a person with chronic Pseudomonas aeruginosa infection. The detailed 
PHWKRGVDQGZRUNHGH[DPSOHVRIFDOFXODWLQJµQRUPDWLYHDGKHUHQFH¶DUHSURYLGHGLQWKHSDSHUE\+RRHW
al.[3] µ1RUPDWLYHDGKHUHQFH¶ is a continuous scale that ranged from 0 (lowest possible adherence level) 
to 100 (highest possible adherence level, due to capping of daily adherence levels at 100%), with higher 
adherence being more desirable.  
 
Severity of anxiety at baseline was self-reported using all seven statements from the General Anxiety 
Disorder 7-item anxiety scale (GAD),[4@HJ µ)HHOLQJQHUYRXVDQ[LRXVRURQHGJH¶Į 7KH*$'
scale ranged from 0 (lowest anxiety severity) to 21 (most severe anxiety).  
 
Severity of depressive disorder at baseline was self-reported using all eight statements from the Patient 
Health Questionnaire depression scale (PHQ-8),[5@ HJ µ/LWWOH LQWHUHVW RU SOHDVXUH LQGRLQJ WKLQJV¶Į  
0.84. The PHQ-8 scale ranged from 0 (lowest depressive disorder severity) to 24 (most severe 
depressive disorder) 
 
Intention at baseline was self-reported using a statement adapted from the Capability Opportunity 
Motivation Behaviour (COM-B) Self Evaluation Questionnaire.[6@7KHVWDWHPHQWXVHGZDV³,ZDQW WRGR
all my prescribed QHEXOLVHUWUHDWPHQWVLQWKHQH[WWZRZHHNV´ZLWKZKLFKSDUWLFLSDQWVUDWHDJUHHPHQWRQ
a scale of 1-7, where 7 represents strongest intention. 
 
Necessity at baseline was self-UHSRUWHG XVLQJ DOO VHYHQ µQHFHVVLW\ VWDWHPHQWV¶ IURP WKH %HOLHIV DERXW
Medicines Questionnaire ± VSHFLILF QHEXOLVHU DGKHUHQFH %04 HJ µ0\ OLIH ZRXOG EH LPSRVVLEOH
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ZLWKRXW WKLV QHEXOLVHU WUHDWPHQW¶ Į    7KH QHFHVVLW\ %04 UDQJHG IURP  ORZHVW SHUFHLYHG
necessity) to 5 (highest perceived necessity). BMQ is a validated self-report tool [7] that was customised 
for the pilot trial to identify perceived necessities and concerns for nebuliser treatment.  
 
Concerns at baseline was self-UHSRUWHG XVLQJ DOO  µFRQFHUQ VWDWHPHQWV¶ IURP WKH %HOLHIV DERXW
Medicines Questionnaire ± specifiF QHEXOLVHU DGKHUHQFH %04 HJ µ, VRPHWLPHV ZRUU\ DERXW
EHFRPLQJWRRGHSHQGHQWRQWKLVQHEXOLVHU¶Į 7KHFRQFHUQ%04UDQJHGIURPORZHVWSHUFHLYHG
concern) to 5 (highest perceived concern). BMQ is a validated self-report tool [7] that was customised for 
the pilot trial to identify perceived necessities and concerns for nebuliser treatment. Necessity and 
concerns are components of conscious motivation. 
 
Habit strength at baseline was self-reported using all four statements from the Self-Report Behavioural 
Automaticity Index (SRBAI),[8@ HJ µGHFLGLQJ WR XVHP\ QHEXOLVHU LV VRPHWKLQJ , GR DXWRPDWLFDOO\¶ Į  
(DFKVWDWHPHQWEHJLQVZLWKµ'HFLGLQJWRXVHP\QHEXOLVHU  «¶WRFDSWXUHKDELWXDO LQVWLJDWLRQ+DELW
strength ranged from 4 (weakest habit) to 20 (strongest habit).  Habit is a component of unconscious 
motivation. 
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Appendix B: Further discussion regarding the strengths and limitations of this study 
 
One of the strengths of this study is that medication adherence was objectively measured using an 
intelligent nebuliser device (eTrack®) that provides time-stamped data on how every dose of nebulised 
medication is being used. We chose to analyse the adherence data over a 3-month post recruitment period 
because baseline objective adherence data (i.e. prior to adherence intervention) was unavailable, sampling 
adherence over shorter periods is an unreliable measure of stable behaviour [1] and adherence were similar 
in both arms of the pilot for the first three months (median 38.5%, IQR 8.7 ± 71.8% for intervention; median 
37.9%, IQR 5.5 ± 54.6% for usual care). Sampling adherence over a 6-month post recruitment period would 
be complicated by the divergence in adherence at month 4±6 (median 33.7%, IQR 7.2 ± 75.0% for 
intervention; median 21.2%, IQR 7.0 ± 55.9% for usual care). 
 
Due to the cross-sectional nature of the analysis, the directionality of the association between habit and 
adherence cannot be established. The relationship between adherence and habit over time is complex; initial 
adherence episodes (undertaken in consistent settings) cause habit to form, and as habit forms, it acquires 
the potential to direct subsequent adherence.[2] While the habit scores analysed were collected at baseline, 
prior to the delivery of any intervention during the pilot trial, ZHGLGQRWKDYHGHWDLOHGGDWDRQSDUWLFLSDQWV¶
adherence (or intervention) histories. It is possible that some of the participants to have been ³VXFFHVVIXOO\
LQWHUYHQHGXSRQ´LQWKHSDVWDQGVRPD\KDYH achieved higher adherence prior to entering the study, and 
maintained these throughout the study. Assuming stability of adherence and habit over time, high adherence 
prior to entering the study may have caused higher habit scores at baseline, which then subsequently 
predicted (in a statistical sense) higher adherence over the following three months. 
 
The habit measure used in this study is the Self-Report Behavioural Automaticity Index (SRBAI),[3] which is 
an automaticity subscale of the Self-Report Habit Index (SRHI).[4] Unlike SRHI, SRBAI does not enquire 
about behaviour frequency.[3] That means it is perhaps less likely for SRBAI scores to be just acting as a 
proxy measure for behaviour frequency. Although changing adherence could potentially change habit (since 
habit is strengthened through consistent repetition of a specific action in a specific context, i.e. content- 
dependent repetition),[2] it is important to note that habit is not synonymous with behaviour (e.g. adherence). 
It is possible that someone using his or her nebuliser frequently to have weak habit if he or she does not use 
the nebuliser in a consistent setting, and instead rely on consciously remembering to use the nebuliser. It is 
also, in theory, possible to strengthen habit without directly increasing the frequency of nebuliser use, by 
instead encouraging more consistent performance.[5] For example, adults with CF might be encouraged to 
identify cues that they encounter reliably and regularly in everyday routines, in the presence of which they 
should use their nebuliser.[6] Such habit-based advice would therefore focus on harnessing potential 
contextual cues, not increasing the frequency of nebuliser use per se. 
 
Although habit was found to be the only independent factor that is associated with nebuliser adherence in 
this study, this is not to say that other factors are irrelevant. Due to modest sample size, the pilot trial could 
only detect differences if the effect size is sufficiently large.[7] For example, a 1 unit decrease in concerns 
score (concerns score could vary from 1, lowest perceived concern to 5, highest perceived concern) was 
associated with a 65% increase in the odds of being in the next-higher adherence category (e.g. from <50% 
to 50±79.9%, or 50± WREXWWKHSLORW trial was not sufficiently powered to detect that effect with a 
FRQYHQWLRQDOĮOHYHORI 
12 
 
It is likely that both reflective (e.g. treatment beliefs) and automatic (e.g. habit) processes are associated with 
adherence levels, which would be detected with larger sample sizes. Nonetheless, we have replicated the 
Sheffield findings in an independent cohort. Replication of results reduces the uncertainty of evidence, hence 
these exploratory studies provide tentative evidence for the role of habit in the health behaviour of using 
nebuliser among adults with CF. The modest sample size for both studies is a limitation, but studies with 
larger sample sizes could still find that habit is more strongly associated with nebuliser adherence compared 
to other factors.  
 
There is only one previous study examining the association between respiratory medication adherence and 
habit strength. The study among 139 asthma patients also found that medication adherence was most 
strongly associated with habit strength compared to other psychological factors such as self-efficacy and 
attitude.[8] In other long-term conditions, habit has been shown to better predict medication adherence 
compared to conscious motivational factors.[9] A recent meta-analysis of 771 medication adherence 
intervention studies identified habit as a promising target for intervention.[10] Therefore, further studies of 
habit as an adherence determinant and the investigation of habit-formation as a potential intervention to 
support adherence should be seen as a priority within cystic fibrosis and other areas of respiratory medicine. 
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